These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21701499)

  • 41. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 42. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.
    Fermaglich LJ; Miller KL
    Orphanet J Rare Dis; 2023 Jun; 18(1):163. PubMed ID: 37353796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

  • 44. Protein replacement therapies for rare diseases: a breeze for regulatory approval?
    Gorzelany JA; de Souza MP
    Sci Transl Med; 2013 Mar; 5(178):178fs10. PubMed ID: 23536010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Four Decades of Orphan Drugs and Priorities for the Future.
    Sinha MS; Stern AD; Rai AK
    N Engl J Med; 2024 Jul; 391(2):100-102. PubMed ID: 38973724
    [No Abstract]   [Full Text] [Related]  

  • 46. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adoption agents.
    Wapner J
    Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
    [No Abstract]   [Full Text] [Related]  

  • 48. Readers Want Reforms of Orphan Drug Act.
    Manag Care; 2017 Jun; 26(6):21. PubMed ID: 28661837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An analysis of FDA-approved drugs for metabolic diseases.
    Kinch MS; Umlauf S; Plummer M
    Drug Discov Today; 2015 Jun; 20(6):648-51. PubMed ID: 25680688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 51. FDA's Office of Orphan Products Development: providing incentives to promote the development of products for rare diseases.
    Patel S; Miller Needleman KI
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):387-393. PubMed ID: 31278433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of orphan drug approval in the European Union.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Eur J Clin Pharmacol; 2008 May; 64(5):545-52. PubMed ID: 18210097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Statistical considerations for rare diseases drug development.
    Chow SC; Chang YW
    J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases.
    Miyamoto BE; Kakkis ED
    Orphanet J Rare Dis; 2011 Jul; 6():49. PubMed ID: 21733145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
    Lutz T; Lampert A; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 57. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of orphan designation status for FDA approved drugs, and case studies in oncology, neuroscience and metabolic diseases.
    Brown DG; Wobst HJ
    Bioorg Med Chem; 2023 Feb; 80():117170. PubMed ID: 36696875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs.
    Bannister JB
    Fordham Law Rev; 2018 Mar; 86(4):1889-921. PubMed ID: 29993206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.